Preparação, estabilidade e conservaçao do fator tecidual ativador de plasminogênio (rt-PA) para uso oftalmológico

Preparação, estabilidade e conservaçao do fator tecidual ativador de plasminogênio (rt-PA) para uso oftalmológico


Juliana M. Ferraz Sallum,
Isabel Batista,
Acácio Alves Souza Lima Filho,
Michel Eid Farah,
Rubens Belfort Jr.


Arquivos Brasileiros de Oftalmologia

versão impressa ISSN 0004-2749versão On-line ISSN 1678-2925

Arq. Bras. Oftalmol. vol.60 no.1 São Paulo fev. 1997



The tissue plasminogen activator (t-PA), a fibrinolitic system component, activates the plasminogen into plasmin, which degrades the fibrin net. The recombinant tissue plasminogen activator has been used in ophthalmology to control the post-operative fibrin formation complications. The comercial t-PA available has a higher dose than necessary in ophthalmology. If it can be shared in doses the coasts will reduced.


To check if the comercial rt-PA, for cardiologic use, can be, diluted and used in ophthalmology, and if the activity remains after storage, and eventualy determine the best storage and utilization methods.

Material and methods:

The rt-PA initial lytic activity was studied on fibrin net substract, and residual activity after long term storage at -20ºC and -70ºC. The material sterility was tested in culture plates.


The rt-PA activity after 6 months storage at -70ºC was 40,7% of non storage rt-PA activity, and at -20ºC it was 34,9%. Samples kept at -20ºC for 6 months and then left at roam temperature 24 hours before testing, showed an activity of 27,9%. No contamination was found in any sample.


The best way tested of storage rt-PA is at -70ºC. And in arder to keep the total potential activity, it should be used immediately after defrost.

Key works: Tissue plasminogen activator; fibrinolysis; fibrin; inflamation


1 AGNELLI, G.; BUCHANAN, M.; FERNANDEZ, F.; BONEU, B.; VAN RYN, J.; HIRSH, J., COLLEN, D. - A comparison of the thrombolytic and hemorrhagic effects of the tissue-type plasminogen activator and streptokinase in rabbits. Circulation, 72: 178-182, 1985.
2 BOLDT, H. C.; ABRAMS, G. W.; MURRAY, T. G.; HAN, D. P.; MIELER, W.F.- The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin. Retina, 12: S75-S79, 1992.
3 CRABBE, S. J. & CLONINGER, C. C. - Tissue plasminogen activator: A new trombolytic agent. Clin Pharm. 6: 373-386, 1987.
4 DAVIDSON, J. F.& WALKER. I. D. - Biological role of fibrinolysis.J. Clin. Pathol., 33: 1-47, 1980.
5 IRVINE, W. D.; JOHNSON, M. W.; HERNANDEZ, E.; OLSEN, K. - Retinal Toxicity of Human Tissue Plasminogen Activator in Vitrectomized Rabbit Eyes. Arch Ophthalmol, 109: 718-722, 1991.
6 JAFFE, G. J.; GREEN, G. D. J., ABRAMS, G. W. - Stability of recombinant tissue plasminogen activator. Am. J. Ophthalmol, 108: 90-91, 1989.
7 PENNICA, D.; HOLMES. W. E.; KOHR, W. J.; HARKINS, R. N.; VEHAR, G. A.; WARD, C. A.; BENNETT, W. F.; YELVERTON, E.; SEEBURG, P.; HEYNEKER, H. L.; GOEDDEL, D. V. - Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature, 301: 214-221, 1983.
8 RIJKEN, D. C. & COLLEN, D.: Puritication and characterization of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem., 256: 7035-7041, 1981.